Inoviq Ltd (AU:IIQ) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
INOVIQ Ltd has successfully completed disease specificity testing for its new breast cancer blood test, showcasing its ability to accurately detect breast cancer with 81% sensitivity and 93% specificity. The test outperforms existing FDA-approved tests by reducing false positives and is being developed for the US market as a laboratory-developed test. This advancement positions INOVIQ as a key player in the breast cancer diagnostics market, with plans to expand its technology to other cancer biomarkers.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue